Cauê Benito Scarim

CV Lattes ORCID Google Scholar Citations

Universidade Estadual Paulista (UNESP). Campus de Araraquara. Faculdade de Ciências Farmacêuticas (FCFAR) (Institutional affiliation from the last research proposal)
Birthplace: Brazil

Currently a student graduate (PhD) in research and development of drugs for neglected disease Universidade Estadual Paulista Julio de Mesquita Filho (UNESP). Master in Pharmaceutical Sciences in the drug development area of #8203;#8203;neglected diseases, the Faculty of Pharmaceutical Sciences (UNESP) - (LAPDESF - Research Laboratory and Development of New Drugs). Where realized stage (FEB / 2013 - JAN / 2014) in the scientific development program in the field of planning, development and synthesis of new compounds, with an emphasis on neglected diseases. He worked with computational chemistry (scientific initiation). Degree in Pharmacy and Biochemistry from the University of West Paulista (UNOESTE / 2009-2012). Experience in Pharmacy, with emphasis on pharmaceutical chemistry and design of new drugs, pathology and histopathology, acting on the following topics: Chagas disease, anti-inflammatory, latentiation and prodrugs. (Source: Lattes Curriculum)

News published in Agência FAPESP Newsletter about the researcher

More items Less items

TITULO

Articles published in other media outlets ( ):

More items Less items

VEICULO: TITULO (DATA)

Scholarships in Brazil

Completed (most recent)

Abstract
Chagas disease, even than a century after its discovery (1909), is still a major public health problem. It is estimated that approximately 10 million people worldwide are infected with Trypanosoma cruzi (T. cruzi). However, the situation is more critical in Latin America and other regions where this disease is endemic. The largest number of cases occurs in Brazil, Bolivia, Argentina and M…
Design, synthesis and characterization of benzofuroxanes coupled to alpha, beta unsaturated carbonyls as cruzain inhibitors, BP.IC
Abstract
Chagas Disease is a major public health problems in Latin America. In Brazil, only benznidazole (BNZ) is available for the treatment of the disease, being active only in the acute phase. Research with hydroxymethylnitrofurazone (NFOH) showed that this compound has anti T. cruzi activity in vitro and in vivo with low toxicity in mutagenicity assays and LD50. Scarim (2016) standardized a me…
Hydroxymethylnitrofurazone (NFOH): activity study in chronic phase of Chagas' Disease in an animal model and synthesis of soluble derivatives, BP.DR

Virtual Library in numbers * Updated data on June 07, 2025

Total / Available in English

2 / 2	Completed scholarships in Brazil

Associated processes

Most frequent collaborators in research granted by FAPESP

Keywords used by the researcher

Health Sciences Pharmacy

Please report errors on the page using this form.

Short URL

Compartilhe esta página

Abstract

Abstract